Callio Therapeutics

Callio Therapeutics is a biotechnology company focused on developing multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. The company is developing next-generation ADCs with differentiated linker and payload technologies to deliver multiple agents to tumor cells, maximizing therapeutic benefit. Their lead program is a dual-payload ADC targeting HER2.

Funding Round: Series A

Funding Amount: $187M

Date: 03-Mar-2025

Investors: Frazier Life Sciences, Jeito Capital, Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital, EDBI

Markets: Biotech, Oncology, Health Care, Medical

HQ: Seattle, Washington, United States

Founded:

Website: http://www.calliotx.com

LinkedIn: https://www.linkedin.com/company/calliotx

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/callio-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/756136-18